Multi-provincial Cohort for Hypertension (MUCH)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to construct hypertension specialized cohort using uniform standards and specifications. This study timely collected multi-dimensional clinical information through electronic medical records, mobile health, data integration, informatics and computer modern techniques, linking self-reported data and big data platforms from different sources to timely obtain the incidence and mortality data, and integrating hypertension cohort samples and the associated clinical records systematically, in order to build a 30-thousand hypertension specialized cohort with fine phenotypic data and blood/urine samples, thus far to provide support for the development of precise medicine research and related industries.

Official Title
-----------------
Multi-provincial Cohort for Hypertension in China

Conditions
-----------------
Hypertension

Intervention / Treatment
-----------------
* Drug: Antihypertensive Agents
* Other: Cardiovascular risk factors


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of hypertension over 18 years old ti sign the informed consent Exclusion Criteria: with life-threatening severe disease, such as severe tumor or AIDs pregnancy or lactating women,or plan to pregnant within half a year, with severe mental disorders participating in clinical trials

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Hospital based hypertension cohort<br> | Drug: Antihypertensive Agents<br>* Single or combination therapy with five type of antihypertensive agents, such as Ca channel blockers, ACE inhibitors, ARBs, diuretics, or beta-blockers.<br>Other: Cardiovascular risk factors<br>* Different level of cardiovascular risk factors associated with genetics, environments and lifestyles.<br>|
| Community based hypertension cohort<br> | Drug: Antihypertensive Agents<br>* Single or combination therapy with five type of antihypertensive agents, such as Ca channel blockers, ACE inhibitors, ARBs, diuretics, or beta-blockers.<br>Other: Cardiovascular risk factors<br>* Different level of cardiovascular risk factors associated with genetics, environments and lifestyles.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Composite end point of major cardiovascular and cerebrovascular events | Composite end point of major cardiovascular and cerebrovascular events | From date of enrollment until date of first documented event or date of death from cardiovascular and cerebrovascular events, whichever came first, assessed up to 3 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| New-onset of cardiovascular events | New-onset of cardiovascular events | From date of enrollment until date of first documented event or date of death from cardiovascular and cerebrovascular events, whichever came first, assessed up to 3 year | 
| New-onset of stroke | New-onset of stroke | From date of enrollment until date of first documented event or date of death from cardiovascular and cerebrovascular events, whichever came first, assessed up to 3 year | 
| Total death | Total death | From date of enrollment until date of death from all cause, assessed up to 3 year | 
| Major bleeding | Major bleeding | From date of enrollment until date of first documented event or date of death from cardiovascular and cerebrovascular events, whichever came first, assessed up to 3 year | 
| Atrial fibrillation | Atrial fibrillation | From date of enrollment until date of first documented event or date of death from cardiovascular and cerebrovascular events, whichever came first, assessed up to 3 year |